AnaptysBio - Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
About
Overview
Strategy
Senior Leadership
Board of Directors
Scientific Advisory Board
Contact
Science
Immune Cell Modulation
Publications
Pipeline
Overview
Rosnilimab
ANB032
ANB033
ANB101
Imsidolimab
Partnerships
Investors / News
Overview
News
Events
Presentations
Goverance
Stock Information
Analyst Coverage
SEC Filings
Investor FAQs
Contact
Careers
Overview
Job Openings
Core Values
Total Rewards Program Highlights
AnaptysBio Culture
Contact
Toggle
Home
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
Home
Anaptys Named a BioSpace 2024 Best Places to Work Winner
Anaptys Named a BioSpace 2024 Best Places to Work Winner
Home
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
Home
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
Home
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors